Quick Links
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo & Sapporo, Japan, September 5, 2011 – Evec, Inc. (”Evec”) and Astellas Pharma Inc. (Tokyo:4503, “Astellas”) today announced that they have entered into a license agreement for one...
Tokyo, August 30, 2011 – Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) announced that it has decided to sell the fixed asset listed below. 1． Details of Fixed Asset to Be Sold Asset:...
Teijin Pharma Limited and Astellas Pharma Inc. announced that they have entered into an exclusive distribution agreement for febuxostat (generic name, development code: TMX-67), a novel drug for...
Follow us
